STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | MicrobiomeTrials← Back to trialsNCT05455658
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-11-17Est. Completion: 2026-06-01
Enrollment target: 33 participants Locations- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
- University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Other microbiome trials you might be interested in
Anatomic Stage IV Breast Cancer AJCC v8HER2-Negative Breast Carcinoma
This phase Ib/II trial tests the safety, best dose and how well gemcitabine and ex vivo expanded allogenic universal don…
Columbus, United StatesEst. completion Oct 31, 2027
Breast AdenocarcinomaHormone Receptor PositiveStage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIB Breast Cancer AJCC v7
This randomized phase III trial studies the best individual therapy for women who have node-negative, estrogen-receptor …
Anniston, United StatesEst. completion Mar 2, 2018